Becton Intrinsic Value Calculation – Becton Dickinson Q3 Earnings: Examining Key Metrics Against Estimates
August 6, 2023
🌥️Trending News
Becton ($NYSE:BDX) Dickinson is a healthcare company that provides medical technology and services for the diagnosis, treatment and monitoring of diseases. The company recently released its third quarter financial results for the period ending June 2023. It is important to analyze some of the key metrics to understand how the company did relative to estimates. This was due to higher pricing, favorable product mix, and cost containment initiatives.
In conclusion, Becton Dickinson’s Q3 earnings beat analyst estimates across all key metrics, indicating that the company is performing well despite the ongoing pandemic. The strong performance was driven by higher pricing, favorable product mix, and cost containment initiatives.
Earnings
The BECTON Q3 earnings report for FY2023 as of June 30 2021 revealed that the company earned a total revenue of 4890.0M USD and net income of 525.0M USD. This is an increase of 5.4% in total revenue and 45.8% in net income when compared to the previous year’s report. In the last three years, BECTON’s total revenue has reached 4878.0M USD.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Becton. More…
| Total Revenues | Net Income | Net Margin |
| 19.05k | 1.58k | 10.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Becton. More…
| Operations | Investing | Financing |
| 2.64k | -2.86k | -1.51k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Becton. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 53.02k | 27.08k | 89.41 |
Key Ratios Snapshot
Some of the financial key ratios for Becton are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 4.0% | 12.2% | 11.8% |
| FCF Margin | ROE | ROA |
| 9.1% | 5.4% | 2.6% |
Share Price
Becton Dickinson released its Q3 earnings on Friday, which saw its stock open at $268.2 and close at $270.8, resulting in a 0.8% increase from the previous closing price of $268.7. This news has investors examining the company’s key metrics against expectations to decide whether or not the stock is worth buying. Analysts are closely monitoring Becton Dickinson’s revenue figures as well as its earnings per share (EPS) numbers for Q3. EPS measures how much a company earns from each share of stock and is often seen as a good indicator of a company’s profitability.
Additionally, investors are paying attention to Becton Dickinson’s margins, which refer to how much money it makes on each sale after factoring in costs. It is clear that the Q3 earnings report from Becton Dickinson is being closely watched by investors. Factors such as revenue, EPS, and margins will all be evaluated to determine if the stock is worth buying at its current value. Live Quote…
Analysis – Becton Intrinsic Value Calculation
At GoodWhale, we have conducted an extensive analysis of BECTON’s fundamentals. Using our proprietary Valuation Line, we have calculated the intrinsic value of BECTON shares at around $261.9. Currently, BECTON stock is trading at $270.8, making it a fair price – albeit slightly overvalued by 3.4%. More…
Peers
Becton, Dickinson and Co is a medical technology company that manufactures and sells medical devices, instruments, and supplies. The company operates in three segments: BD Medical, BD Biosciences, and BD Diagnostics. It offers a wide range of products, including syringes, needles, catheters, blood collection devices, IV administration and infusion products, safety products, and sharps disposal systems. The company competes with Penumbra Inc, Teleflex Inc, SheerVision Inc, and other medical technology companies.
– Penumbra Inc ($NYSE:PEN)
Founded in 2002, Umbra is a leading global provider of shading and decorative products. The company’s products are sold in over 120 countries and include a wide range of blinds, shades, drapery hardware, and curtain rods. Headquartered in Toronto, Canada, Umbra employs over 1,200 people worldwide.
Umbra’s market cap is 7.01B as of 2022. The company’s Return on Equity is -2.31%.
The company’s products are sold in over 120 countries and include a wide range of blinds, shades, drapery hardware, and curtain rods.
– Teleflex Inc ($NYSE:TFX)
Teleflex Incorporated is a diversified global provider of medical technologies designed to improve the health and quality of people’s lives. The Company provides solutions for critical care, anesthesia, surgical, urology and emergency medicine.
– SheerVision Inc ($OTCPK:SVSO)
SheerVision Inc is a US-based company that manufactures and sells ophthalmic surgical instruments and devices. The company has a market cap of 140.32k as of 2022 and a Return on Equity of -70.28%. SheerVision’s products are used by eye surgeons to correct vision problems such as nearsightedness, farsightedness, and astigmatism. The company’s products are sold through a network of distributors and retailers worldwide.
Summary
Investors are advised to consider Becton Dickinson’s Q3 performance and future outlook in their decision-making process when determining whether to invest in the company.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
